MedTech startups often mistakenly adopt rigid processes for FDA compliance. The FDA doesn't dictate how you build software; it requires you to define your own robust development process and prove you follow it consistently. Focus on translating your existing workflows into the language of regulatory compliance, rather than changing them.

Contrary to typical agile discovery, projects in high-stakes environments benefit from starting with extremely strict processes and documentation. This establishes a compliant foundation. Flexibility can be introduced later, once core requirements and constraints are fully mastered, rather than starting loose and adding rigor.

Instead of immediately scaling up the manufacturing process between clinical Phase 1 and 2, it is strategically better to produce more batches using the established Phase 1 process. This approach builds critical knowledge about process parameters and CQAs through repetition and increased clinical exposure.

A great molecule isn't enough to attract investment. Scientists must demonstrate they've considered manufacturing from day one. Designing a robust process that fits a consistent GMP facility shows investors that the project is not just a scientific curiosity but a viable path to a scalable product.

Instead of building costly in-house GMP capabilities early on, a more effective strategy is to concentrate on the core preclinical science. By partnering with established CDMOs and consultants for the translation to GMP, startups can de-risk development and accelerate their timeline to an IND filing.

Quality Control is more than a compliance function; it's a vantage point for understanding systemic process inefficiencies. By mastering QC workflows—from raw materials to product release—one can gain the deep operational insights needed to lead large-scale process improvements and even redesign entire manufacturing facilities.

Regulatory issues are not single mistakes but a culmination of tiny, unmonitored errors. Instead of a final compliance check, bake governance into every step of the process to proactively flag issues as they happen, preventing catastrophic failures down the line.

The primary challenge for many MedTech innovations is not the initial science but translating a lab process into a robust, scalable, and GMP-compliant manufacturing system. This requires a shift from proving a concept to ensuring consistent quality and patient safety.

A process that seems simple in a development lab is often not viable in a strict GMP manufacturing environment. To create truly manufacturable therapies, process development scientists need direct, hands-on exposure to GMP constraints and workflows to avoid significant rework and delays.